Clinical Trials
Open
Phase
Accrual
66%
SWOG Clinical Trial Number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Status Notes
Arm 2 will be Permanently Closed to Accrual and Arms 1 & 3 will be Reopened to Accrual as of 02/15/2024, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Closed
Phase
Accrual
64%
SWOG Clinical Trial Number
S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Status Notes
Status Notes: Permanently Closed to Accrual 04/07/2025, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
12-15-2020
ClinicalTrials.gov Registry Number
04647916
Open
Phase
Accrual
68%
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S2001
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
Closed
10-23-2025
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
42%
SWOG Clinical Trial Number
S1931
Phase III trial of Nivolumab and Ipilimumab with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Status Notes
Active effective 11/16/2020
Research Committee(s)
Genitourinary Cancer
Activated
11-16-2020
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Status Notes
Permanent Closure to Accrual, Effective June 18, 2024, at 3:00 PM Eastern Time.
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013
Closed
Phase
Accrual
99%
SWOG Clinical Trial Number
S1904
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Status Notes
This study is approaching the overall accrual target, therefore, it will be permanently closed to new patient accrual, effective June 14, 2024, at 12:00 p.m. PT.
Research Committee(s)
Prevention & Epidemiology
Breast Cancer
Activated
09-01-2020
ClinicalTrials.gov Registry Number
NCT 04496739
Open
Phase
Accrual
36%
SWOG Clinical Trial Number
S1905
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Status Notes
Re-opened to accrual effective: 10/02/2023.
Research Committee(s)
Leukemia
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S1933
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1929
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)
Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
Closed
12-15-2022
ClinicalTrials.gov Registry Number
04334941
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1823
A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors
Status Notes
This study was permanently closed to new patient accrual, effective May 20, 2024. This closure does not affect enrolled patients. Submission of specimens and data continue per protocol.
Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
Phase
Accrual
87%
SWOG Clinical Trial Number
S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S1900B
A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900B will close to accrual April 30, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-10-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900C
A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)
Status Notes
S1900C closed to accrual December 18, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-16-2020
Closed
12-18-2020
Closed
Phase
Accrual
45%
SWOG Clinical Trial Number
S1827
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Status Notes
This study is approaching the overall accrual target and will be permanently closed to Registration on December 15, 2025, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034
Open
Phase
Accrual
83%
SWOG Clinical Trial Number
S1922
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Status Notes
Permanently closed to accrual, effective December 01, 2022, 12:00 p.m. Pacific Time
Research Committee(s)
Lymphoma
Activated
07-19-2019
Closed
12-01-2022
ClinicalTrials.gov Registry Number
03907488
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1803
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Status Notes
This study is closed to accrual effective 1/15/25 at 12:00 PM PST. This closure does not apply to Registration Step 2 and Registration Step 3 randomization.
Research Committee(s)
Myeloma
Activated
06-27-2019
Closed
01-15-2025
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S1916
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
Status Notes
This study is permanently closed effective September 16, 2020.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1800A
A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Status Notes
S1800A closed to accrual November 16, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
05-17-2019
Closed
11-16-2020